ATXN2 and amyotrophic lateral sclerosis: This approach not only benefits ATXN2-ALS patients but also offers a therapeutic avenue for a broader spectrum of ALS patients, as TDP-43 localization to ATXN2-dependent stress granules represents a common pathological endpoint.